Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient

A 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagihara, Masao, Imai, Yui, Uchida, Tomoyuki, Ohara, Shin, Inoue, Morihiro, Sugi, Tomiyuki, Mitamura, Keiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381351/
https://www.ncbi.nlm.nih.gov/pubmed/35850990
http://dx.doi.org/10.2169/internalmedicine.9513-22
_version_ 1784769060454531072
author Hagihara, Masao
Imai, Yui
Uchida, Tomoyuki
Ohara, Shin
Inoue, Morihiro
Sugi, Tomiyuki
Mitamura, Keiko
author_facet Hagihara, Masao
Imai, Yui
Uchida, Tomoyuki
Ohara, Shin
Inoue, Morihiro
Sugi, Tomiyuki
Mitamura, Keiko
author_sort Hagihara, Masao
collection PubMed
description A 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the anti-SARS CoV-2 vaccine, BNT162b2, was administered, which improved his blood cell count and eliminated the virus. The increased anti-spike IgG titer and lymphocyte count after vaccination suggested that both humoral and cellular immunity acted in coordination to eliminate the virus.
format Online
Article
Text
id pubmed-9381351
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-93813512022-08-31 Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient Hagihara, Masao Imai, Yui Uchida, Tomoyuki Ohara, Shin Inoue, Morihiro Sugi, Tomiyuki Mitamura, Keiko Intern Med Case Report A 52-year-old man with mantle cell lymphoma treated with bendamustine and rituximab developed prolonged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Despite elevated titers of anti-spike IgG antibody, protracted pancytopenia persisted for more than six months. Finally, the anti-SARS CoV-2 vaccine, BNT162b2, was administered, which improved his blood cell count and eliminated the virus. The increased anti-spike IgG titer and lymphocyte count after vaccination suggested that both humoral and cellular immunity acted in coordination to eliminate the virus. The Japanese Society of Internal Medicine 2022-07-15 2022-07-15 /pmc/articles/PMC9381351/ /pubmed/35850990 http://dx.doi.org/10.2169/internalmedicine.9513-22 Text en Copyright © 2022 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hagihara, Masao
Imai, Yui
Uchida, Tomoyuki
Ohara, Shin
Inoue, Morihiro
Sugi, Tomiyuki
Mitamura, Keiko
Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title_full Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title_fullStr Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title_full_unstemmed Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title_short Successful Elimination of SARS-CoV-2 Following Vaccination with BNT162b2 after Prolonged Viral Infection in an Immunocompromised Lymphoma Patient
title_sort successful elimination of sars-cov-2 following vaccination with bnt162b2 after prolonged viral infection in an immunocompromised lymphoma patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381351/
https://www.ncbi.nlm.nih.gov/pubmed/35850990
http://dx.doi.org/10.2169/internalmedicine.9513-22
work_keys_str_mv AT hagiharamasao successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT imaiyui successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT uchidatomoyuki successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT oharashin successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT inouemorihiro successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT sugitomiyuki successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient
AT mitamurakeiko successfuleliminationofsarscov2followingvaccinationwithbnt162b2afterprolongedviralinfectioninanimmunocompromisedlymphomapatient

Ejemplares similares